Reading CYTK? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CYTK free→Reading CYTK? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CYTK free→NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, while management's recent track record has been steady and capital-friendly. The company was unprofitable over the past year, so its earnings quality can't be assessed. The sector backdrop is a headwind, and compared with sector peers, it is below typical. If CYTK cuts guidance on the next call, that's a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $75.21. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.63x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
1 material management or governance event in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-1.68 → $-1.64 (+2.2% / 30d). 9 raised, 3 cut, 15 covering analysts.
0 upgrades, 0 downgrades / 30d. 86% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$149.
How much price usually moves either way.
On a bad day, this stock has moved -$406.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,501.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Better cash flow shows improved efficiency. This is important for financial health.
Confirms:Cash from operations improves to less than -$130M in Q2.
Disproves:Cash from operations worsens to more than -$150M in Q2.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CYTK yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
and under Exhibit 99.1 shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Registrant expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CYTK Cytokinetics | Below typical Show detailsSector percentile: 27 of 100 | — | moderate |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 77 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on controlling and reducing operating expenses to improve financial performance.
Leverage strategic partnerships to drive revenue growth and expand market presence.
Improve cash flow from operations to strengthen financial stability and support growth initiatives.
Why it matters: These results will show if aficamten helps patients with non-obstructive HCM. Positive results could boost confidence in the drug's potential.
Confirms:ACACIA-HCM shows clear gains in symptoms. It also improves exercise performance.
Disproves:Results show no clear gains when compared to placebo.
Why it matters: A slowdown in growth could affect Cytokinetics' results and future plans.
Confirms:Sector revenue growth reported below the median of 10% in the next quarter.
Disproves:Sector revenue growth remains above the median of 10%.
Why it matters: FDA approval would expand aficamten's label, increasing its market potential. This is key for future revenue growth.
Confirms:The FDA approves the sNDA for MAPLE-HCM. This allows more use of aficamten.
Disproves:The FDA denies the sNDA for MAPLE-HCM. This limits aficamten's market potential.
Why it matters: Effective cost management is key to improving financial health and cash flow.
Confirms:Operating costs drop by at least 10% from last quarter.
Disproves:Operating costs go up or stay the same from last quarter.
Why it matters: A successful launch in Germany would expand MYQORZO's market and revenue potential. This is crucial for growth.
Confirms:The launch is successful. First prescriptions are given and providers give positive feedback.
Disproves:The launch does not get initial prescriptions or positive feedback from providers.
Why it matters: Partnerships can increase sales and support the company's growth plans.
Confirms:At least one new partnership is expected to bring in over $10M.
Disproves:No new partnerships announced in the next quarter.
Why it matters: High operating costs can mean issues with managing expenses. This can lower profits.
Confirms:Operating expenses rise more than 5% quarter over quarter in Q2.
Disproves:Operating expenses drop or stay the same from last quarter in Q2.
Why it matters: Strong revenue growth would show that Cytokinetics is successfully leveraging partnerships. This is key for future growth.
Confirms:Q2 revenue grew over 20% compared to last year. This shows strong partnership performance.
Disproves:Q2 revenue growth is below 10% year over year, suggesting weak partnership impact.
Other Events. Underwriting Agreement On May 6, 2026, Cytokinetics, Incorporated (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the public offering, issuance and sale (the “Offering”) of 9,859,155 shares of the Company’s common stock, par value $0.…
and under Exhibit 99.1 shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Registrant expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.